Oryzon Genomics
Oryzon Genomics S.A. is a clinical phase biopharmaceutical company based in Cornellà de Llobregat, Spain, specializing in the discovery and development of epigenetics-based therapeutics for cancer and central nervous system (CNS) disorders. The company is focused on developing targeted therapies, and its clinical pipeline includes iadademstat, a selective LSD1 inhibitor currently in Phase II trials for oncology, and vafidemstat, a CNS-optimized LSD1 inhibitor also in Phase II trials for neurological diseases. Additionally, Oryzon is advancing ORY-3001, a selective LSD1 inhibitor in preclinical development aimed at treating non-oncological conditions, alongside other compounds at various stages of development. Founded in 2000, Oryzon leverages its epigenetic platform to identify biomarkers and therapeutic targets, fostering the creation of personalized medicine.
Crystax
Acquisition in 2009
Crystax Pharmaceuticals is a biopharmaceutical company specializing in structure-based drug discovery. The firm focuses on identifying and developing new lead compounds for therapeutic applications, particularly in cancer treatment. Crystax employs a combination of structural and biophysical techniques, including X-ray crystallography, NMR, fragment screening, and hit optimization through biophysical analysis and computational chemistry. By utilizing these advanced methods, the company aims to accelerate the drug discovery process and deliver higher quality molecules to the market.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.